<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02582710</url>
  </required_header>
  <id_info>
    <org_study_id>5714</org_study_id>
    <nct_id>NCT02582710</nct_id>
  </id_info>
  <brief_title>Impact of an Optimized Formulation of Omega 3 on the Composition of Atheromatous Plaques in Patients Requiring Carotid Endarterectomy</brief_title>
  <acronym>POMEGA</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Determining whether treatment with an optimized formulation of omega 3 for 6 weeks causes a&#xD;
      40% decrease in the average concentration of total microparticles (MPs) in the atheromatous&#xD;
      plaque.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related postive event assessed by the reduction of the concentration of procoagulant microparticles in the atherosclortic plaque</measure>
    <time_frame>an average of 1 to 6 months after the carotid endarterectomy</time_frame>
    <description>Microparticle concentration measured by captured-based prothrombinase assay</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related modification of the content of the plaque assessed by protein biomarkers of the plaque instability and thrombogenicity, and by the identification of the cell origin of the procoagulant microparticles</measure>
    <time_frame>an average of 1 to 6 months after the carotid endarterectomy</time_frame>
    <description>Number of patients with treatment-related modifications in the concentration of blood biomarkers of thrombogenicity. Comparisons of plaque and blood biomarkers variations related to the treatment Description field : Cell origin of MPs measured prothrombinase assay after capture on cell lineage specific antibodies. Detection of proteases and biomakers by western blot or activity assays.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Carotid Endarterectomy</condition>
  <arm_group>
    <arm_group_label>VASCAZEN</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients treated with Vascazen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients treated with a placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>VASCAZEN</intervention_name>
    <description>6 weeks treatment with an optimized formulation of omega 3 before the carotid endarterectomy</description>
    <arm_group_label>VASCAZEN</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>PLACEBO</intervention_name>
    <description>6 weeks treatment with a placebo before the carotid endarterectomy</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men or women between 30 and 85 years&#xD;
&#xD;
          -  Affiliated to a social security scheme&#xD;
&#xD;
          -  Informed consent signed&#xD;
&#xD;
          -  Patients to get an endarterectomy carotid stenosis&gt; 70% asymptomatic is&#xD;
&#xD;
          -  Women of childbearing potential (negative pregnancy test), effective contraception for&#xD;
             the duration of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to give informed information about the study (subject in emergencies,&#xD;
             difficulty of understanding ...)&#xD;
&#xD;
          -  Patient treated by OMACORÂ®&#xD;
&#xD;
          -  Patients on oral anticoagulant (AVK, apixaban, dabigatran, rivaroxaban)&#xD;
&#xD;
          -  Daily consumption of fish oil (medical food with fish oil (omega 3))&#xD;
&#xD;
          -  Carotid Restenosis&#xD;
&#xD;
          -  Pregnancy (positive pregnancy test) and lactation&#xD;
&#xD;
          -  Hypersensitivity to fish&#xD;
&#xD;
          -  Allergy to fish&#xD;
&#xD;
          -  Subject under judicial protection&#xD;
&#xD;
          -  Subjects under guardianship or curatorship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yannick GEORG, MD</last_name>
    <email>yannick.georg@chru-strasbourg.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nouvel Hopital Civil</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yannick GEORG, MD</last_name>
      <email>yannick.georg@chru-strasbourg.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>September 29, 2015</study_first_submitted>
  <study_first_submitted_qc>October 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2015</study_first_posted>
  <last_update_submitted>October 20, 2015</last_update_submitted>
  <last_update_submitted_qc>October 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

